| Document Date: 2008-09-19 00:16:04
Open Document File Size: 37,31 KBShare Result on Facebook
City Tokyo / Deerfield / / Company ASTELLAS PHARMA US INC. / Astellas Pharma Inc. / / Country United States / / / Event FDA Phase / / / IndustryTerm immune systems / pharmaceutical market / pharmaceutical products / pharmaceutical / / MedicalCondition esophageal candidiasis / hemolytic anemia / HIV / common bloodstream infection / shock / anaphylaxis / serious hypersensitivity / candidemia and other Candida infections / Candidemia Invasive candidiasis / hepatic failure / hypersensitivity / fungal infection / hepatitis / renal dysfunction / pruritus / bloodstream infection / rash / clinically significant hepatic dysfunction / Infectious Disease / acute renal failure / Candida infection / / Organization Food and Drug Administration / Center for Disease Control / / Person Yoshihiko Hatanaka / Maribeth Landwehr / / / Position President and Chief Executive Officer / / Product cyclosporine / MYCAMINE / ANTIFUNGAL PRODUCT MYCAMINE® Submission / MYCAMINE® (micafungin sodium) / / ProvinceOrState Illinois / / Technology transplantation / / URL www.astellas.com/us / http /
SocialTag |
Media Contacts: Maribeth Landwehr[removed]removed]